U.S. Markets close in 6 hrs 25 mins

Verve Therapeutics, Inc. (VERV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
44.90+0.39 (+0.88%)
As of 9:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close44.51
Bid41.50 x 1200
Ask45.99 x 800
Day's Range44.81 - 44.90
52 Week Range29.50 - 78.00
Avg. Volume361,553
Market Cap2.07B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est79.50
  • GlobeNewswire

    Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

    CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer and Andrew Bellinger, M.D., Ph.D., chief scientific officer and chief medical officer, will participate in a fireside chat during the Jefferies Gene Therapy/Editing Summit on Thursday, October 28, 2021 at 9:00 a.m. ET.

  • Motley Fool

    2 Gene-Editing Stocks to Have on Your Radar Right Now

    They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.

  • Insider Monkey

    Cathie Wood Stock Portfolio: 10 Newest Stock Picks This Year

    In this article, we discuss Cathie Wood stock portfolio: 10 newest stock picks this year. If you want to skip our detailed analysis of these stocks, go directly to Cathie Wood Stock Portfolio: 5 Newest Stock Picks This Year. Cathie Wood is a well-known star stock picker who manages disruptive innovation-focused portfolios through her ETFs. […]